BPMC - Blueprint Medicines Corp - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

BPMC is currently covered by 20 analysts with an average price target of $127.22. This is a potential upside of $25.53 (25.11%) from yesterday's end of day stock price of $101.69.

Blueprint Medicines Corp's activity chart (see below) currently has 256 price targets and 261 ratings on display. The stock rating distribution of BPMC is 82.05% BUY, 12.82% HOLD and 5.13% SELL.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 74.34% with an average time for these price targets to be met of 257.58 days.

Highest price target for BPMC is $151, Lowest price target is $100, average price target is $120.

Most recent stock forecast was given by ANDREW FEIN from HC WAINWRIGHT on 02-May-2025. First documented stock forecast 26-May-2015.

Currently out of the existing stock ratings of BPMC, 64 are a BUY (82.05%), 10 are a HOLD (12.82%), 4 are a SELL (5.13%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$135

$33.31 (32.76%)

$135

16 days ago
(02-May-2025)

10/17 (58.82%)

$30.36 (29.01%)

283

Buy

$130

$28.31 (27.84%)

$133

20 days ago
(28-Apr-2025)

13/23 (56.52%)

$41.49 (46.88%)

73

Buy

$128

$26.31 (25.87%)

$124

1 months 2 days ago
(16-Apr-2025)

16/20 (80%)

$45.89 (55.89%)

270

Hold

$100

$-1.69 (-1.66%)

$168

1 months 28 days ago
(20-Mar-2025)

5/7 (71.43%)

$11.53 (13.03%)

179

Buy

$150

$48.31 (47.51%)

$132

2 months 11 days ago
(07-Mar-2025)

3/5 (60%)

$61.46 (69.41%)

168

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is BPMC (Blueprint Medicines Corp) average time for price targets to be met?

On average it took 257.58 days on average for the stock forecasts to be realized with a an average price target met ratio 74.34

Which analyst has the current highest performing score on BPMC (Blueprint Medicines Corp) with a proven track record?

RENI BENJAMIN

Which analyst has the most public recommendations on BPMC (Blueprint Medicines Corp)?

Reni Benjamin works at JMP and has 2 price targets and 5 ratings on BPMC

Which analyst is the currently most bullish on BPMC (Blueprint Medicines Corp)?

Salveen Richter with highest potential upside - $66.31

Which analyst is the currently most reserved on BPMC (Blueprint Medicines Corp)?

Liana Moussatos with lowest potential downside - -$26.69

Blueprint Medicines Corp in the News

Blueprint Medicines Stock Up Despite Lower-Than-Expected Q1 Earnings

Blueprint Medicines Corporation BPMC reported first-quarter 2025 adjusted loss of 74 cents per share, which was wider than the Zacks Consensus Estimate of a loss of 42 cents. The adjusted figure excludes the one-time equity investment gain of $50 million recorded in the reported quarter, following the closing of GSK’s acquisition of IDRx. The company incurred a...

Blueprint Medicines Corp (BPMC) Q1 2025 Earnings Call Highlights: Strong AYVAKIT Revenue Growth ...

AYVAKIT Revenue: $149.4 million in global net product revenues, with $129.4 million from the US and $20 million from ex-US markets. Revenue Growth: 61% year-over-year growth in AYVAKIT revenue. Revenue Guidance: Raised to $700 million to $720 million for the year. Cash Position: Strong cash position of $900 million. Operating Expenses: Incremental increase in R&D...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?